Verve Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
Verve Therapeutics (VERV), a clinical-stage biotech company focused on genetic medicines for cardiovascular disease, has granted equity awards to seven new employees under its 2024 Inducement Stock Incentive Plan. The grants include:
- Stock options for 134,860 shares at $5.67 per share, vesting over 4 years with 25% after year one and monthly thereafter
- 65,398 restricted stock units (RSUs) vesting equally over three years starting July 1, 2025
These grants were made as employment inducements in compliance with Nasdaq Listing Rule 5635(c)(4).
Verve Therapeutics (VERV), una società biotecnologica in fase clinica specializzata in terapie genetiche per le malattie cardiovascolari, ha assegnato premi azionari a sette nuovi dipendenti nell’ambito del suo Piano di Incentivi Azionari 2024. Le assegnazioni comprendono:
- Opzioni su 134.860 azioni a un prezzo di 5,67 dollari per azione, con maturazione in 4 anni, il 25% dopo il primo anno e il resto mensilmente
- 65.398 unità azionarie vincolate (RSU) con maturazione uguale distribuita su tre anni a partire dal 1° luglio 2025
Queste assegnazioni sono state concesse come incentivi all’assunzione in conformità con la Regola 5635(c)(4) del Nasdaq.
Verve Therapeutics (VERV), una empresa biotecnológica en etapa clínica centrada en medicamentos genéticos para enfermedades cardiovasculares, ha otorgado premios accionarios a siete nuevos empleados bajo su Plan de Incentivos de Acciones 2024. Las concesiones incluyen:
- Opciones sobre 134,860 acciones a 5,67 dólares por acción, con adquisición durante 4 años, 25% después del primer año y el resto mensualmente
- 65,398 unidades de acciones restringidas (RSU) con adquisición equitativa durante tres años a partir del 1 de julio de 2025
Estas concesiones se otorgaron como incentivos de contratación en cumplimiento con la Regla 5635(c)(4) de Nasdaq.
Verve Therapeutics (VERV)는 심혈관 질환을 위한 유전자 치료제에 중점을 둔 임상 단계 바이오텍 회사로, 2024년 유인 주식 인센티브 계획에 따라 7명의 신입 직원에게 주식 보상을 부여했습니다. 보상 내용은 다음과 같습니다:
- 주당 5.67달러에 134,860주의 스톡옵션, 4년에 걸쳐 취득하며 1년 후 25% 취득, 이후 매월 취득
- 2025년 7월 1일부터 3년에 걸쳐 균등하게 취득하는 65,398 제한 주식 단위(RSU)
이 보상은 Nasdaq 상장 규칙 5635(c)(4)에 따라 고용 유인책으로 제공되었습니다.
Verve Therapeutics (VERV), une société biotechnologique en phase clinique spécialisée dans les médicaments génétiques pour les maladies cardiovasculaires, a attribué des actions à sept nouveaux employés dans le cadre de son Plan d’Incitation à l’Actionnariat 2024. Les attributions comprennent :
- Des options d’achat de 134 860 actions à 5,67 dollars par action, acquises sur 4 ans avec 25 % après la première année, puis mensuellement
- 65 398 unités d’actions restreintes (RSU) acquises également sur trois ans à partir du 1er juillet 2025
Ces attributions ont été faites en tant qu’incitations à l’embauche conformément à la règle 5635(c)(4) du Nasdaq.
Verve Therapeutics (VERV), ein biotechnologisches Unternehmen in der klinischen Phase, das sich auf genetische Medikamente für Herz-Kreislauf-Erkrankungen spezialisiert hat, hat sieben neuen Mitarbeitern im Rahmen seines Inducement Stock Incentive Plans 2024 Aktienzuteilungen gewährt. Die Zuteilungen umfassen:
- Aktienoptionen für 134.860 Aktien zu je 5,67 USD, die über 4 Jahre mit 25 % nach dem ersten Jahr und anschließend monatlich vesten
- 65.398 Restricted Stock Units (RSUs), die gleichmäßig über drei Jahre ab dem 1. Juli 2025 vesten
Diese Zuteilungen wurden als Anreize zur Einstellung gemäß Nasdaq Listing Rule 5635(c)(4) gewährt.
- None.
- None.
BOSTON , May 02, 2025 (GLOBE NEWSWIRE) -- Verve Therapeutics, a clinical-stage company developing a new class of genetic medicines for cardiovascular disease, today announced that on April 30, 2025, the company granted equity awards to seven new employees, pursuant to the company’s 2024 Inducement Stock Incentive Plan, as an inducement material to each new employee entering into employment with the company in accordance with Nasdaq Listing Rule 5635(c)(4).
The employees received stock options to purchase an aggregate of 134,860 shares of the company’s common stock and an aggregate of 65,398 restricted stock units (RSUs). The options have an exercise price of
About Verve Therapeutics
Verve Therapeutics, Inc. (Nasdaq: VERV) is a clinical-stage company developing a new class of genetic medicines for cardiovascular disease with the potential to transform treatment from chronic therapies to single-course gene editing medicines. The company’s lead programs –VERVE-102, VERVE-201, and VERVE-301 – target the three cholesterol drivers of atherosclerosis: LDL-C, triglycerides, and Lp(a). VERVE-102 is designed to permanently turn off the PCSK9 gene in the liver and is being developed initially for heterozygous familial hypercholesterolemia (HeFH) and ultimately to treat patients with established atherosclerotic cardiovascular disease (ASCVD) who continue to be impacted by high LDL-C levels. VERVE-201 is designed to permanently turn off the ANGPTL3 gene in the liver and is initially being developed for refractory hypercholesterolemia, where patients still have high LDL-C despite treatment with maximally tolerated standard of care therapies, and homozygous familial hypercholesterolemia (HoFH). VERVE-301 is designed to permanently turn off the LPA gene to reduce Lp(a) levels. Lp(a) is a genetically validated, independent risk factor for ASCVD, ischemic stroke, thrombosis, and aortic stenosis. For more information, please visit www.VerveTx.com.
Investor Contact
Jen Robinson
Verve Therapeutics, Inc.
jrobinson@vervetx.com
Media Contact
Ashlea Kosikowski
1AB
ashlea@1abmedia.com
FAQ
What equity awards did Verve Therapeutics (VERV) grant to new employees in April 2025?
What is the vesting schedule for VERV's April 2025 stock option grants?
How do the RSUs vest in Verve Therapeutics' April 2025 inducement grants?
What was the exercise price for VERV's April 2025 inducement stock options?
